PAVmed Inc. Series Z Warrant
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more
PAVmed Inc. Series Z Warrant (PAVMZ) - Total Assets
Latest total assets as of March 2025: $52.82 Billion USD
Based on the latest financial reports, PAVmed Inc. Series Z Warrant (PAVMZ) holds total assets worth $52.82 Billion USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PAVmed Inc. Series Z Warrant - Total Assets Trend (2014–2024)
This chart illustrates how PAVmed Inc. Series Z Warrant’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PAVmed Inc. Series Z Warrant - Asset Composition Analysis
Current Asset Composition (December 2024)
PAVmed Inc. Series Z Warrant's total assets of $52.82 Billion consist of 7058.1% current assets and -6958.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $18.00K | 0.1% |
| Inventory | $266.00K | 0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how PAVmed Inc. Series Z Warrant's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PAVmed Inc. Series Z Warrant's current assets represent 7058.1% of total assets in 2024, an increase from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 99.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 0.9% of total assets.
PAVmed Inc. Series Z Warrant Competitors by Total Assets
Key competitors of PAVmed Inc. Series Z Warrant based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
PAVmed Inc. Series Z Warrant - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PAVmed Inc. Series Z Warrant generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, PAVmed Inc. Series Z Warrant generates $ 129.78 in net profit.
PAVmed Inc. Series Z Warrant - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.37 | 0.54 | 0.38 |
| Quick Ratio | 0.37 | 0.52 | 0.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.14 Billion | $ -25.44 Million | $ -13.38 Million |
PAVmed Inc. Series Z Warrant - Advanced Valuation Insights
This section examines the relationship between PAVmed Inc. Series Z Warrant's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -7.4% |
| Total Assets | $30.66 Million |
| Market Capitalization | $13.21K USD |
Valuation Analysis
Below Book Valuation: The market values PAVmed Inc. Series Z Warrant's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PAVmed Inc. Series Z Warrant's assets decreased by 7.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PAVmed Inc. Series Z Warrant (2014–2024)
The table below shows the annual total assets of PAVmed Inc. Series Z Warrant from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $30.66 Million | -7.42% |
| 2023-12-31 | $33.12 Million | -38.65% |
| 2022-12-31 | $53.98 Million | -37.94% |
| 2021-12-31 | $86.98 Million | +339.76% |
| 2020-12-31 | $19.78 Million | +173.16% |
| 2019-12-31 | $7.24 Million | -14.78% |
| 2018-12-31 | $8.50 Million | +418.18% |
| 2017-12-31 | $1.64 Million | +88.38% |
| 2016-12-31 | $870.42K | -28.31% |
| 2015-12-31 | $1.21 Million | +44.18% |
| 2014-12-31 | $842.08K | -- |